DOSSIER · 13F-HR · Q3 2026

REGENERON PHARMACEUTICALS, INC.

$180M in tracked AUM across 3 positions as of Q3 2026.

RP
CIK 0000872589 · last filed Sep 30, 2026
Total AUM
$180M
as of Q3 2026
Holdings
3
+0 QoQ
positions
Whale Score
71
71
strong
Activity
0
+0 new, −0 sold
changes this Q
AI Analysis · Q3 2026

REGENERON PHARMACEUTICALS, INC. filed its latest 13F-HR for Q3 2026. 0 position changes this quarter — 0 new, 0 exited, 0 added, 0 trimmed.

Quarter at a glance — Q3 2026

0 material changes this filing.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q3 2026. Source: SEC EDGAR 13F-HR filings.

#HoldingValueSharesWeight
01
PBLS
Parabilis Medicines, Inc.
$135M4.2M74.9%
02
NTLA
Intellia Therapeutics, Inc.
$45M3.7M24.9%
03
ACET
Adicet Bio, Inc.
$432K61K0.2%

Filing history

2026Q3Sep 30
$180M▲ 1.4%
3 positionsView →
2026Q2Jun 30
$177M▲ 270.1%
3 positionsView →
2026Q1Mar 31
$48M▲ 41.7%
2 positionsView →
2025Q4Dec 31
$34M▼ 95.2%
2 positionsView →
2025Q3Sep 30
$700M▼ 52.9%
3 positionsLocked
2025Q2Jun 30
$1.5B▲ 21.0%
4 positionsLocked
2025Q1Mar 31
$1.2B▲ 12.1%
4 positionsLocked
2024Q4Dec 31
$1.1B—
6 positionsLocked